Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Accumulated Expenses (2022 - 2025)

Stoke Therapeutics has reported Accumulated Expenses over the past 4 years, most recently at $41.0 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $41.0 million for Q4 2025, up 433.89% from a year ago — trailing twelve months through Dec 2025 was $41.0 million (up 433.89% YoY), and the annual figure for FY2025 was $41.0 million, up 433.89%.
  • Accumulated Expenses for Q4 2025 was $41.0 million at Stoke Therapeutics, up from $30.1 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for STOK hit a ceiling of $41.0 million in Q4 2025 and a floor of $1.7 million in Q1 2024.
  • Median Accumulated Expenses over the past 4 years was $13.6 million (2022), compared with a mean of $15.0 million.
  • Biggest five-year swings in Accumulated Expenses: crashed 88.0% in 2024 and later skyrocketed 1372.17% in 2025.
  • Stoke Therapeutics' Accumulated Expenses stood at $15.7 million in 2022, then fell by 12.27% to $13.8 million in 2023, then crashed by 44.36% to $7.7 million in 2024, then soared by 433.89% to $41.0 million in 2025.
  • The last three reported values for Accumulated Expenses were $41.0 million (Q4 2025), $30.1 million (Q3 2025), and $25.6 million (Q2 2025) per Business Quant data.